Researchers at the Garvan Institute of Medical Research in Sydney have identified a previously overlooked immune defect behind mevalonate kinase deficiency, a rare inflammatory disorder, in a study published this week in the journal Immunity.
The finding points to an experimental treatment already approved for other conditions.
The disorder, known as MKD, affects hundreds of children and adults worldwide, and scientists suspect many cases remain undiagnosed, ScienceDaily reported. For roughly three decades, research centered on macrophages, immune cells that coordinate inflammatory defenses, and existing treatments were designed to block a signal those cells release. About half of patients do not respond adequately, leaving many families without effective options.
The new work suggests the primary problem lies elsewhere. In people with MKD, natural killer cells, which normally destroy infected cells early in a viral infection, fail to mature properly. Their toxic granules stay trapped inside, and when the cells cannot kill their targets, they compensate by flooding the body with interferon gamma, a powerful inflammatory signal that drives the dangerous fever and widespread inflammation patients experience during severe episodes.
“This really turns on its head 30 years of dogma about what was thought to be the underlying mechanism of disease. In MKD, the primary problem is in NK cells and not in macrophages, as previously believed,” she says.
Clinical Takeaway: JAK Inhibitors May Help MKD
- A rare inherited disease once blamed mainly on one immune cell type appears to be partly driven by a different one that malfunctions during infections.
- Existing anti-inflammatory drugs called JAK inhibitors may help patients who don’t respond to current therapies, though this remains unproven at scale.
- Anyone with recurrent high fever, rash, and abdominal inflammation should raise a possible MKD diagnosis with a specialist, since many cases go undetected.
How a Failed Kill Switch Turns Into a Fever Storm
Professor Mike Rogers, Lab Head at Garvan and senior author, described the cellular defect in concrete terms. NK cells carry “toxic ammunition” in granules designed to destroy infected cells. In MKD, those granules cannot be released.
“However, in MKD these toxic granules can’t be released from NK cells and remain trapped inside. When an NK cell fails to kill its target, it compensates by shouting for help, pumping out large amounts of interferon gamma – a powerful inflammatory signal. This activates other immune cells and causes the dangerous fever and widespread inflammation seen in patients.”
That signal activates other immune cells and triggers the flares that can become life-threatening. The Garvan team reached this picture by examining blood samples from people with MKD and studying preclinical models of the disorder, working with Professor Mariapia Degli-Esposti and scientists at Monash University. In those models, when the immune system could not clear a viral infection, the resulting inflammatory response damaged organs extensively.
This reframing matters because patients experience recurring attacks of high fever, skin rashes, joint pain, and abdominal inflammation, and the most serious episodes can be fatal. A mechanism rooted in NK cell failure helps explain why a disease of defective immune defense also produces runaway inflammation, ScienceDaily reported.
An Already-Approved Drug Gets a Second Look
The discovery has already shaped an experimental treatment for a severely affected infant. Working with doctors at the Royal Children’s Hospital in Melbourne, the researchers added baricitinib, a JAK inhibitor, to the child’s regimen. These drugs interfere with signaling pathways the immune system uses, including responses to interferon gamma. Baricitinib is already prescribed for rheumatoid arthritis and eczema.
The outcome was encouraging but limited in scope. Inflammatory flares became less frequent, and severe inflammation affecting the gastrointestinal tract began to heal. The researchers caution that a single patient cannot establish whether the treatment works more broadly — an important constraint, since case-level improvement in a severely selected patient does not predict trial-level efficacy.
“This study has revealed a new target for this inflammatory disorder and sets the scene for future clinical studies to explore the use of JAK inhibitors or other drugs to neutralize interferon gamma in patients with MKD,” says Professor Mike Rogers, Lab Head at Garvan and senior author of the study. “This could lead to a targeted treatment that hasn’t been tried before.”
Because the proposed approach relies on medications already approved for other immune conditions, themorning.science noted, it may be faster to test in patients than an entirely new compound.
Regulatory agencies such as the FDA in the United States and the EMA in Europe would still require dedicated clinical evidence before endorsing JAK inhibitors specifically for MKD, a rare disease that will demand carefully designed small trials rather than large conventional ones.
What the Two Research Camps Still Disagree On
ScienceDaily presents the finding as a direct overturning of three decades of doctrine, anchored in Munoz’s own words about the dogma being turned on its head. themorning.science emphasizes the practical angle: because the candidate treatment uses existing medications, the path to patient testing may be shorter.
Neither outlet reports a published dissent from the macrophage-centered school of MKD research, which has defined the field since the 1990s, so whether the older framework fully gives way remains an open scientific question.
Beyond MKD: The “Prenylopathies” Hypothesis
The researchers suggest the findings could affect more areas. They have introduced the term “prenylopathies” for a family of genetic disorders involving the same metabolic pathway affected in MKD, the mevalonate pathway, which is central to cellular chemistry. Early findings suggest these related diseases may share the same underlying flaw: NK cells that malfunction and instead generate excessive inflammatory signals.
If further studies confirm the connection, common mechanisms across several disorders could be identified and treated with common targets.
Rogers tied that possibility to a problem familiar to rare-disease families: “Confirming this link could help end the diagnostic odyssey many patients endure for years or even decades before receiving effective treatment,” he said, ScienceDaily reported. Both researchers hold conjoint appointments at St Vincent’s Clinical School, Faculty of Medicine and Health, UNSW Sydney.
| Approach | Target cell | Status | Who may benefit |
|---|---|---|---|
| Current standard treatments | Macrophage inflammatory signal | Established, but inadequate in roughly half of patients | Responsive patients |
| JAK inhibitors (e.g., baricitinib) | Interferon gamma signaling; NK cell defect axis | Experimental for MKD; single case reported | Patients unresponsive to standard therapy |
MKD Requires Specialist Care Before Trying Baricitinib
Because baricitinib for MKD remains experimental, no patient should start or change this therapy without a specialist in autoinflammatory disease. MKD itself warrants medical attention when episodes of high fever recur with rash, joint pain, or abdominal inflammation, and urgent care is required when a flare produces severe symptoms or signs of organ involvement. The Garvan team’s findings describe a research direction, not a validated prescribing change.
The Road to a Confirmatory Trial
The immediate next step, per the researchers, is clinical study design: trials testing JAK inhibitors or other drugs that block interferon gamma in MKD patients, especially those who have not benefited from standard treatments. A single infant’s improvement is a hypothesis generator, not proof of efficacy.
Dr. Marcia Munoz, Group Leader in the Rogers Lab and lead researcher on the study, says the results represent a major change in how scientists understand the disease, telling ScienceDaily that the primary problem in MKD is in NK cells rather than macrophages. If confirmatory trials bear that out, MKD would become one of the clearest examples of a rare disease rewriting the understanding of its own biology.
References
- The new study on NK cell dysfunction in mevalonate kinase deficiency, published in the journal Immunity (Garvan Institute of Medical Research, 2026), as reported by ScienceDaily.
- themorning.science, “A rare disease reveals a hidden flaw in the immune system” (themorning.science).
- ScienceDaily, “A rare disease reveals a hidden flaw in the immune system,” featuring Prof. Mike Rogers and Dr. Marcia Munoz, Garvan Institute of Medical Research / UNSW Sydney.